Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Liquidia Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Liquidia 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Tarsus Pharmaceuticals Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Tarsus Pharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Vanda Pharmaceuticals Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Vanda Pharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Ventyx Biosciences Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Ventyx Biosciences 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Arbutus Biopharma Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Arbutus Biopharma 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Merkel Cell Carcinoma Indication Strategy Report 2026: PD-1, DLL3, Trials and Deal Outlook
20 July 2026
A 2026 Merkel cell carcinoma strategy report covering elderly burden, PD-1 and DLL3 biology, clinical competition, deal signals and portfolio positioning.
Latest Hotspot
8 min read
Anal Squamous Cell Carcinoma Indication Strategy Report 2026: PD-1, EGFR, Trials and Deal Outlook
20 July 2026
A 2026 anal squamous cell carcinoma strategy report covering HPV burden, PD-1 and EGFR biology, clinical competition, deal signals and portfolio positioning.
Latest Hotspot
8 min read
Testicular Germ Cell Tumor Indication Strategy Report 2026: KIT, PARP1, Trials and Deal Outlook
20 July 2026
A 2026 testicular germ cell tumor strategy report covering young-adult burden, KIT and PARP1 biology, clinical competition, deals and portfolio positioning.
Latest Hotspot
8 min read
Thymic Carcinoma Indication Strategy Report 2026: KIT, PD-1, Trials and Deal Outlook
20 July 2026
A 2026 thymic carcinoma strategy report covering disease burden, KIT and PD-1 biology, clinical competition, deal signals and portfolio positioning.
Latest Hotspot
8 min read
Malignant Mesothelioma Indication Strategy Report 2026: Mesothelin, BAP1, Trials and Deal Outlook
20 July 2026
A 2026 malignant mesothelioma strategy report covering asbestos burden, mesothelin and BAP1 biology, clinical competition, deal signals and portfolio positioning.
Latest Hotspot
8 min read
Retinoblastoma Indication Strategy Report 2026: MDM2, E2F1, Trials and Deal Outlook
20 July 2026
A 2026 retinoblastoma strategy report covering childhood burden, MDM2 and E2F1 biology, clinical competition, deal activity and portfolio positioning.
Latest Hotspot
8 min read
Neuroblastoma Indication Strategy Report 2026: GD2, ALK, Trials and Deal Outlook
20 July 2026
A 2026 neuroblastoma strategy report covering childhood burden, GD2 and ALK biology, clinical competition, deal activity and portfolio positioning.